| 0.0837 0 (0%) | 10-14 14:55 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.19  |
1-year : | 0.22 |
| Resists | First : | 0.16 |
Second : | 0.19 |
| Pivot price | 0.03  |
|||
| Supports | First : | 0.06 |
Second : | 0 |
| MAs | MA(5) : | 0.03 |
MA(20) : | 0.03 |
| MA(100) : | 0.01 |
MA(250) : | 0.01 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.4 |
D(3) : | 22.2 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 0.16 | Low : | 0 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AMPE ] has closed below upper band by 23.9%. Bollinger Bands are 88.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.08 - 0.08 | 0.08 - 0.08 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
Mon, 25 Mar 2024
Ampio Announces Voluntary Delisting and SEC Deregistration - PR Newswire
Thu, 11 Jan 2024
Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions - PR Newswire
Thu, 31 Aug 2023
Ampio Pharmaceuticals Announces Reverse Stock Split - PR Newswire
Fri, 14 Oct 2022
Ampio Pharmaceuticals Issues Letter to Stockholders - Stock Titan
Sun, 09 Oct 2022
AMPE Stock Price and Chart — OTC:AMPE - TradingView
Sun, 24 Jul 2022
6 Penny Stocks With 1,000% Upside Potential - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 35 (K) |
| EPS | -10.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61.6 % |
| Return on Equity (ttm) | -114 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|